Share

    


In This Section

Home / Learn / Cancer Types / Liver Cancer

Liver Cancer

Liver cancer, which includes hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally, responsible for more than 700,000 deaths worldwide each year.

Although this cancer type is less common in the United States, the American Cancer Society estimates that for 2021,42,230 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed and about 30,230 individuals will die of these cancers nationwide.

In the U.S., incidence rates of liver cancer in young adults have started to decline; however, the incidence of liver cancer in adults has more than tripled over the last 40 years. Nationally, death rates from liver cancer have increased by about one percent each year for women and have stabilized for men.

Effective prevention and treatment strategies for liver cancer remain an area of need. Active research in liver cancer is underway as several new therapies, including multikinase inhibitors and checkpoint inhibitor immunotherapy, have been approved to treat liver cancer, with more showing promise.

Multidisciplinary Hepatocellular Carcinoma Care

ACCC identified effective practices in multidisciplinary care hepatocellular carcinoma (HCC) and is providing peer-to-peer learning and resources for effective care coordination and communication.
Learn More

“HCC is a difficult disease to manage because of the multiple components of care required – no single provider can address all needs. A multidisciplinary approach puts patients at the center and results in better experience and outcomes.”

Joel Wedd headshotJoel Wedd, MD, MPH
Director of the Liver Tumor Clinic Emory Transplant Center, Emory Healthcare
end-quote
 
 

Explore this program:

Effective Practices Publication

Results from cancer program case studies illustrate the complexities of the disease and care planning and reinforce the value of a multidisciplinary approach. Learn practical tips for improving communication and care coordination across the multidisciplinary cancer care team and with patients.

Liver Cancer Heatmap

Access ACCC’s Liver Cancer Heatmap to better understand the current incidence, mortality rates, and health disparities that exist across the United States.

HCC Resource Hub

Explore this curated resource bank to learn more about screening and treatment guidelines, training opportunities, patient education, and clinical trials for HCC.

From Oncology Issues

  •  Making the Case for an HIV Oncology Clinic
    By Marco A. Ruiz, MD
    Though the incidence of AIDS-defining cancers (Kaposi’s sarcoma, non-Hodgkin lymphoma, and invasive cervical carcinoma) has decreased with the use of antiretroviral therapy, numerous studies suggest that non-AIDS-defining cancers (cancers not previously associated with HIV and AIDS) appear to be increasing in incidence.
  •  Highlights from ASCO 2018
    By Cary A. Presant, MD, FACP, FASCO
    ASCO 2018 offered a wealth of new data that will continue to transform clinical practice and cancer program development. Most important, implementation of the scientifi c advances we learned at ASCO 2018 will improve the length and quality of life of our cancer patients.

ACCCBuzz Blog Posts


REFERENCES

  1. American Cancer Society.Cancer Facts and Figures, 2021 [https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html]

  2. American Cancer Society. Key Statistics about Liver Cancer [https://www.cancer.org/cancer/liver-cancer/about/what-is-key-statistics.html]

  3. Bucco D.  Promising Liver Cancer Treatments on the Horizon. Cure Today. [https://www.curetoday.com/view/promising-liver-cancer-treatments-on-the-horizon]

  4. Dobkowski, D. Patients with HCC Positively Respond to Opdivo with Yervoy When Nexavar Was Not an Option [https://www4.curetoday.com/view/patients-with-hcc-positively-respond-to-opdivo-with-yervoy-when-nexavar-was-not-an-option]